Form 4: Xenon Pharmaceuticals Director Gary Patou Receives Significant Equity Awards

Xenon Pharmaceuticals Inc. Director Gary Patou has acquired 17,012 share options and 2,645 restricted share units, aligning his interests with the company's long-term performance.

Summary

• Gary Patou, a Director of Xenon Pharmaceuticals Inc. (XENE), was granted 17,012 share options and 2,645 Restricted Share Units (RSUs) on June 5, 2025.
• The share options have an exercise price of $30.73 and are set to expire on June 4, 2035.
• Both the share options and the Restricted Share Units will vest 100% on the earlier of June 4, 2026, or the day before the issuer's 2026 annual meeting of shareholders.
• Following these transactions, Mr. Patou directly beneficially owns 17,012 share options and 2,645 Restricted Share Units.

Sentiment

Score: 7

Explanation: The acquisition of equity awards by a director is generally a positive signal, indicating alignment of interests and confidence in the company's future. However, it's a routine compensation disclosure rather than a significant operational or financial announcement.

Positives

• The acquisition of share options and Restricted Share Units by a director indicates continued confidence in the company's future prospects and aligns management's incentives with shareholder value.
• The long-term vesting schedule, extending to June 2026, encourages sustained commitment and performance from the director.

Negatives

• No direct negatives are identified in this Form 4 filing, as it primarily reports routine equity compensation awards.

Risks

• No specific risks are mentioned in this Form 4 filing, which is a standard disclosure of insider equity transactions.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance regarding the company's future financial performance or strategic outlook, as its purpose is solely to disclose insider equity transactions.

Industry Context

This Form 4 filing details an individual director's equity compensation, which is a common practice across industries to align executive and director incentives with shareholder value. It does not provide broader industry trends or competitive analysis.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential positive impact due to increased alignment of the director's interests with long-term shareholder value and company performance.

Next Steps

• Vesting of the acquired share options and Restricted Share Units will occur on the earlier of June 4, 2026, or the day before Xenon Pharmaceuticals' 2026 annual meeting of shareholders.

Key Dates

Recommendation

Keywords

Xenon Pharmaceuticals, XENE, SEC Form 4, Insider Transaction, Equity Awards, Share Options, Restricted Share Units, Director Compensation, Corporate Governance